About Us
Overview
Business Model
Milestones
Our Presence
Board of Directors
Committees of Board
Management Team
Corporate Governance Report
Mission, Vision & Values
Environment

Vertical Integration     Business Flexibility

At Granules, our extensive integration empowers us to meet the unprocessed, semi-processed and processed product needs of our customers
  • Facilities capable of manufacturing products throughout the entire pharmaceutical manufacturing value chain.

  • One of the world’s largest granulation (PFI) plants with a batch-size of 6 MT.

  • Large capacity facilities for Paracetamol and Ibuprofen.

  • Strategic product portfolio focused on high-volume products, such as Paracetamol, Ibuprofen, Guaifenesin, Metformin and other related PFIs and formulations.

  • Catering to a select range of quality-conscious pharmaceutical players.

  • Continually grow capacities commensurately across the value chain.

  • Enlisting a growing number of API/PFI customers for formulations; leverage marketing infrastructure to gain new customers.

Partnerships/Relationships     Long-term Commitments

At Granules, we strive to be among the largest suppliers in specific products within the global pharmaceutical markets.
  • Supplier of Paracetamol, Ibuprofen, Metformin, Guaifenesin and other related PFIs and formulations to the regulated and quality-conscious markets of the U.S., Europe, Australia, Canada and Latin America.

  • Focus on strengthening relationships with select global MNCs, remain close to their development and add value through our offices in India, U.S., U.K., China and Colombia.

  • Extensive integration provides a growing scope to enhance volumes across select products.

  • Infrastructure designed for large-scale production.

  • One of the largest capacities in the world for Paracetamol, Ibuprofen and Metformin catering to varying customer needs.

Finished Dosages     High Growth Products

At Granules, we are integrated across the pharmaceutical manufacturing value chain – from APIs to PFIs to FDs.
  • Able to manufacture multi-dosage forms – tablets, capsules, press-fits, effervescent tablets, sachets and gel caps (soft and hard).

  • Multi-Packaging Capabilities - Bulk, Blister, Bottle.

  • Installed a capacity to produce six billion tablets annually, scalable to 12 billion tablets annually .

  • Since 2008, we have filed several ANDAs and currently have 2 approved ANDAs.

  • Dedicated Module for coloured contaminating products.

  • Received U.S.FDA, TGA and EU approval for our formulations facility.